Phase I Study to Determine the Maximum Tolerated Dose and Evaluate the Pharmacokinetics of Intrapleural Bevacizumab After Pleural Drainage in Patients With Symptomatic Malignant Pleural Effusion in the Context of Breast Cancer

Trial Profile

Phase I Study to Determine the Maximum Tolerated Dose and Evaluate the Pharmacokinetics of Intrapleural Bevacizumab After Pleural Drainage in Patients With Symptomatic Malignant Pleural Effusion in the Context of Breast Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Breast cancer; Malignant pleural effusion
  • Focus Adverse reactions
  • Acronyms BEVAP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 May 2017 Planned End Date changed from 1 Dec 2019 to 15 Dec 2017.
    • 09 May 2017 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top